

Treatment of reactive hypoglycemia with macrobiotic Ma-Pi 2 diet as assessed by continuous glucose monitoring system

Submission date 02/02/2016	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 05/02/2016	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 29/04/2016	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Reactive hypoglycemia (RH) is a disorder where levels of glucose (sugar) in the blood become dangerously low following a meal (called hypoglycemic episodes). Nutritional therapy is recommended for people affected by RH. The macrobiotic Ma-Pi 2 diet is a nutritional therapy that improves glucose control in people with type 2 diabetes. The aim of this study is to investigate whether the Ma-Pi 2 diet improves blood glucose levels in patients affected by RH.

Who can participate?

Patients diagnosed with RH, aged 26 to 65.

What does the study involve?

Patients are randomly allocated to one of two groups. One group receives the control (low-glycemic index) diet for 3 days followed by the macrobiotic Ma-Pi 2 diet for a further 3 days. The other group receives the Ma-Pi 2 diet and then the control diet. All participants' blood glucose levels are measured throughout the study by using continuous glucose monitoring devices and glucometers.

What are the possible benefits and risks of participating?

There may be immediate direct benefits to the subjects participating - i.e. reduction of the number of hypoglycemic episodes. The main risk could be a drastic decrease in glucose levels and to avoid it participants will be strictly monitored by the doctors and specialists involved.

Where is the study run from?

The Endocrinology Area of the University of Campus Biomedico of Rome (Italy).

When is the study starting and how long is it expected to run for?

February 2014 to February 2015

Who is funding the study?

UPM Un Punto Macrobiotico International Association (Italy)

Who is the main contact?

1. Professor Paolo Pozzilli (p.pozzilli@unicampus.it)
2. Dr Andreea Soare (a.soare@unicampus.it)

Contact information

Type(s)

Scientific

Contact name

Prof Paolo Pozzilli

Contact details

Via Alvaro del Portillo 21

Rome

Italy

00128

+39 (0)6 22541 9184

p.pozzilli@unicampus.it

Additional identifiers

Protocol serial number

51/14

Study information

Scientific Title

A randomized crossover trial to assess the effect of the Ma-Pi 2 MAcrobiotic diet in the treatment of reactive HYPoglycemia with continuous glucose monitoring system (MAHYP)

Acronym

MAHYP

Study objectives

This study is designed to determine whether short-term administration of the macrobiotic Ma-Pi 2 diet improves metabolic control in non-diabetic subjects affected by reactive hypoglycemia (reduction of the number of hypoglycemic episodes and assessment of glycemc distributions through different readings by continuous glucose monitoring system) compared with a low-GI diet for reactive hypoglycemia – to date, there is no diet for treating this condition.

The null hypothesis is that there will be no reduction of the number of hypoglycemic episodes or that there will be no difference according to the dietary sequence administered.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The Ethics Committee of the University Campus Bio-Medico of Rome, 30/09/2014, prot. 51/14

Primary study design

Interventional

Study design

Interventional crossover single-centre trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Reactive hypoglycemia

Interventions

The subjects enrolled in the study are randomized and consequently divided into two homogeneous groups to receive the two dietary treatments in opposite sequence. Over a period of 6 days they are lodged in a farm in Italy, where they receive all daily meals (Ma-Pi 2 Macrobiotic meals or a control low-GI diet for reactive hypoglycemia).

Anthropometrical measurements will be carried out at baseline and after 6 days of the dietary interventions. Glucose profile measurements will be performed throughout the trial by using continuous glucose monitoring and glucometers.

Intervention Type

Other

Primary outcome(s)

Reduction of the number of episodes of reactive hypoglycemia (blood glucose level below 70 mg/dL) in patients affected by such condition during macrobiotic Ma-Pi 2 diet administration compared to a same period during the administration of a low-GI diet.

Key secondary outcome(s)

Glycemic distributions assessment through different readings (< 40; 41-50; 51-60; 61-70, 71-80, 81-90, 91-100, 101-110, 111-120, 121-130, 131-140, 141-150, 151-160, 161-170, 171-180 and > 180 mg/dL), measured and compared between the two dietary treatments

Completion date

28/02/2015

Eligibility

Key inclusion criteria

1. Non-diabetic patients
2. Both sexes
3. Aged at least 18 years old
4. BMI between 18 and 35 kg/m²
5. Able to provide written informed consent and to follow the procedures of the protocol
6. Previous diagnosis of RH, though it was confirmed by MMT before the enrolment

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Impaired fasting glucose/impaired glucose tolerance/diabetic patients
2. Subjects affected by insulinoma or by other hypoglycemic endocrine conditions
3. Patients affected by any neoplasia
4. Patients affected by any food behavior disorders
5. Pregnant women
6. Symptoms of hypocalcemia
7. Known or suspected hypersensitivity to any of the ingredients of the administered diets
8. Patients under vitamin K antagonists or corticosteroid treatment
9. Subjects under any drugs therapy which might interfere with glucose metabolism

Date of first enrolment

01/10/2014

Date of final enrolment

31/01/2015

Locations**Countries of recruitment**

Italy

Study participating centre

Campus Bio-Medico University of Rome

Via Alvaro del Portillo 21

Rome

Italy

00128

Sponsor information**Organisation**

UPM Un Punto Macrobiotico International Association (Italy)

Funder(s)

Funder type

Charity

Funder Name

UPM Un Punto Macrobiotico International Association (Italy)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Available on request